
Phase 1 Data Prolong Pharmaceuticals to Present Preliminary PP-007 Findings for AIS at 2025 ISC
Prolong Pharmaceuticals to Present Preliminary Phase 1 Data for PP-007 in AIS at 2025 ISC Phase 1 Data Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, is poised to make a significant contribution to the field of acute ischemic stroke (AIS)…